He Yan-Na, Meng Yi, Gao Na-Na, Zhang Bing-Jie, Li Huan, Ji Sha-Sha
Department of Pediatric Rehabilitation, Jiaozuo Maternal and Child Health Care Hospital, Jiaozuo 454100, Henan Province, China.
Department of Neurological Rehabilitation, Henan Province Hospital of TCM.
Zhongguo Zhen Jiu. 2020 Aug 12;40(8):839-44. doi: 10.13703/j.0255-2930.20190525-0003.
To compare the effect of acupoint injection and intramuscular injection with mouse nerve growth factor (mNGF) on gross motor function development of children with cerebral palsy (CP), and explore the treatment mechanism.
A total of 63 children with CP were randomly divided into an observation group (32 cases, 4 cases dropped off ) and a control group (31 cases, 3 cases dropped off). Based on the routine rehabilitation therapy, the control group received intramuscular injection of mNGF(18 µg/2 mL), and the observation group received acupoint injection of mNGF at Xinshu (BL 15), Ganshu (BL 18), Pishu (BL 20), Shenshu (BL 23), Sanjiaoshu (BL 22), Shenting (GV 24), Baihui (GV 20), Fengfu (GV 16), Dazhui (GV 14), etc. Of them, 5-6 acupoints alternately were selected each time, and each acupoint was given 0.3-0.5 mL, totally 18 µg/2 mL. Both treatment were carried out once every other day for six months. Before and after treatment, the children's development of brain function was assessed using gross motor function classification system (GMFCS). Before treatment (T), after 2 (T), 4 (T) and 6 (T) months of treatment, the motor function was evaluated by gross motor function measure (GMFM-88). The systolic peak velocity (Vs), mean velocity (Vm) and vascular resistance index (RI) of anterior cerebral artery (ACA) and middle cerebral artery (MCA) were measured, and the level of N-acetyl aspartate acid (NAA), choline (Cho), lactate (Lac) and creatine (Cr) from the basal ganglia, thalamus and periventricular white mater were detected by magnetic resonance spectroscopy (MRS) technology with MAGNETOM Skyra3.0T magnetic resonance imaging system before and after treatment.
Compared with before treatment, the GMFCS classification of the observation group after treatment was significantly improved (<0.05); after treatment, the difference of GMFCS classification between the two groups was not significant (>0.05), however, the observation group had a 3.142 times of feasibility for good gross motor function development by more than level 1 compared to the control group (<0.05). After 2, 4, and 6 months of treatment, the GMFM-88 scores of the two groups showed an upward trend (<0.01), and the increase of the observation group was greater than that of the control group (<0.05). Compared with before treatment, in the ACA and MCA, the Vs and Vm increased, RI decreased in both groups after treatment (<0.01), and in the brain, NAA/Cr increased, Cho/Cr and Lac/Cr decreased (<0.01), and after treatment, the Vs, Vm of ACA and MCA and NAA/Cr of brain in the observation group were higher than those in the control group (<0.05), and the RI of ACA and MCA and Cho/Cr and Lac/Cr of brain in the observation group were lower than those in the control group (<0.05).
The mNGF acupoint injection has a better effect on the gross motor function in the children with cerebral palsy compared with the intramuscular injection, and the mechanism may be associated with exhibiting the double effects of acupoint effect and the targeting therapy of drug, which can effectively improve the cerebral hemodynamics and the metabolism of cerebral nervous substances.
比较穴位注射与肌肉注射小鼠神经生长因子(mNGF)对脑瘫(CP)患儿粗大运动功能发育的影响,并探讨其治疗机制。
将63例CP患儿随机分为观察组(32例,脱落4例)和对照组(31例,脱落3例)。在常规康复治疗基础上,对照组采用肌肉注射mNGF(18μg/2mL),观察组采用mNGF穴位注射,穴位选取心俞(BL15)、肝俞(BL18)、脾俞(BL20)、肾俞(BL23)、三焦俞(BL22)、神庭(GV24)、百会(GV20)、风府(GV16)、大椎(GV14)等,每次交替选取5~6个穴位,每个穴位注射0.3~0.5mL,共18μg/2mL。两组均隔日治疗1次,共治疗6个月。治疗前后采用粗大运动功能分类系统(GMFCS)评估患儿脑功能发育情况。治疗前(T0)、治疗2个月(T2)、4个月(T4)及6个月(T6)后,采用粗大运动功能测量量表(GMFM-88)评估运动功能。测量大脑前动脉(ACA)和大脑中动脉(MCA)的收缩期峰值流速(Vs)、平均流速(Vm)及血管阻力指数(RI),并采用MAGNETOM Skyra3.0T磁共振成像系统,通过磁共振波谱(MRS)技术检测治疗前后基底节、丘脑及脑室旁白质的N-乙酰天门冬氨酸(NAA)、胆碱(Cho)、乳酸(Lac)及肌酸(Cr)水平。
与治疗前比较,观察组治疗后GMFCS分级明显改善(P<0.05);治疗后两组GMFCS分级差异无统计学意义(P>0.05),但观察组粗大运动功能发育良好(提高1个级别以上)的可能性是对照组的3.142倍(P<0.05)。治疗2、4、6个月后,两组GMFM-88评分均呈上升趋势(P<0.01),且观察组升高幅度大于对照组(P<0.05)。与治疗前比较,治疗后两组ACA、MCA的Vs、Vm升高,RI降低(P<0.01),脑内NAA/Cr升高,Cho/Cr、Lac/Cr降低(P<0.01);治疗后观察组ACA、MCA的Vs、Vm及脑内NAA/Cr高于对照组(P<0.05),ACA、MCA的RI及脑内Cho/Cr、Lac/Cr低于对照组(P<0.05)。
与肌肉注射相比,mNGF穴位注射对脑瘫患儿粗大运动功能的改善效果更好其机制可能与发挥穴位效应和药物靶向治疗的双重作用有关,可有效改善脑血流动力学及脑神经物质代谢。